IMCD N.V.
4.3.2026 08:00:00 CET | Globenewswire | Press release
IMCD nominates Andreas Igerl as CCO and member of the Management Board
IMCD nominates Andreas Igerl as CCO and member of the Management Board
Rotterdam, the Netherlands (4 March 2026) – IMCD N.V. ("IMCD" or "Company"), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, is pleased to announce that its Supervisory Board nominates Andreas Igerl to become Chief Commercial Officer (CCO) and member of the Management Board.
Andreas Igerl, in his role as CCO, will strengthen the Management Board with his international experience and will further drive commercial excellence within IMCD. In addition, he will continue to head the EMEA region and the Industrial Business Groups.
Andreas Igerl (born 1980, German) joined IMCD in 2019 and he currently serves as Executive Committee member and President IMCD EMEA and Industrial Business Groups. Before, he held positions as President for IMCD Asia-Pacific, Managing Director IMCD China and Business Unit Manager Advanced Materials in Germany. He holds a master’s degree in business administration from the University of Applied Science for Economy and Management in Munich.
Janus Smalbraak, Chair of the Supervisory Board: “Andreas is a pragmatic leader, with strong focus on execution and a collaborative style. This nomination supports IMCD’s increased focus on supplier relationships, customer centricity and commercial excellence.”
The proposal to appoint Andreas Igerl as member of the Management Board will be submitted for approval at the Annual General Meeting to be held on 30 April 2026. With the proposed appointment, the Management Board of IMCD will consist of a total of three members, reflecting the current size of the company and the ambition for further long-term growth and market leadership.
- xxx-
This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation and was issued on 4 March 2026, 08:00 a.m. CET.
About IMCD
IMCD, based in Rotterdam, The Netherlands, is a leading global partner for the distribution and formulation of speciality chemicals and ingredients. IMCD is an expert solutions provider and adds sustainable value to the supply chain. Every day professionals focus on providing the best service through commercial and operational excellence. The company is mindful of the role they play in creating a better planet for all and formulates with consciousness and executes with care, to address business challenges of tomorrow, in partnership and transparency.
In 2025, with over 5,200 employees, IMCD realised revenues of EUR 4,779 million. IMCD N.V.’s shares are traded at Euronext Amsterdam (symbol: IMCD) and included in the Dutch ESG AEX index, as one of 25 companies within the AEX and AMX indices demonstrating best ESG practices.
For further information, please visit www.imcdgroup.com
Media contact
Muriel Werlé
Corporate Communications Director
+31 10 290 86 14
mediarelations@imcdgroup.com
Investor relations contact
Tosca Holtland
Head of Investor Relations
+31 10 290 86 53
ir@imcdgroup.com
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S24.10.2026 13:00:00 CEST | Press release
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
ASYAD24.10.2026 12:47:36 CEST | Press release
Asyad Group to Host Muscat Maritime Resilience Forum to Strengthen Global Trade Networks
King Faisal Specialist Hospital & Research Centre24.10.2026 11:00:00 CEST | Press release
KFSH Extends Emergency Access Through Virtual Care and Specialist Coordination
Orion Oyj24.10.2026 08:35:00 CEST | Press release
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
Zymeworks Inc.24.10.2026 08:30:00 CEST | Press release
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom